A deep Chandra observation of the interacting star-forming galaxy Arp 299

We present results from a 90 ks Chandra ACIS-S observation of the X-ray luminous interacting galaxy system Arp 299 (NGC 3690/IC 694). We detect 25 discrete X-ray sources with luminosities above 4.0x10^38 erg s^-1 covering the entire Ultra Luminous X-ray source (ULX) regime. Based on the hard X-ray spectra of the non-nuclear discrete sources identified in Arp 299, and their association with young, actively star-forming region of Arp 299 we identify them as HMXBs. We find in total 20 off-nuclear sources with luminosities above the ULX limit, 14 of which are point-like sources. Furthermore we observe a marginally significant deficit in the number of ULXs, with respect to the number expected from scaling relations of X-ray binaries with the star formation rate (SFR). Although the high metalicity of the galaxy could result in lower ULX numbers, the good agreement between the observed total X-ray luminosity of ULXs, and that expected from the relevant scaling relation indicates that this deficit could be the result of confusion effects. The integrated spectrum of the galaxy shows the presence of a hot gaseous component with kT = 0.72+-0.03 keV, contributing 20% of the soft (0.1-2.0 keV) unabsorbed luminosity of the galaxy. A plume of soft X-ray emission in the west of the galaxy indicates a large scale outflow. We find that the AGN in NGC 3690 contributes only 22% of the observed broad-band X-ray luminosity of Arp 299.Comment: 20 pages, 14 figures, 9 tables. Accepted for publication in MNRA

Abundance and temperature of the outer hot circum-Galactic medium: The SRG/eROSITA view of the soft X-ray background in the eFEDS field

Despite their vital importance to understand galaxy evolution and our own Galactic ecosystem, our knowledge of the physical properties of the hot phase of the Milky Way is still inadequate. However, sensitive SRG/eROSITA large area surveys are now providing us with the long sought-after data needed to mend this state of affairs. We present the properties of the soft X-ray emission as observed by eROSITA in the eFEDS field. We measure the temperature and metal abundance of the hot circum-Galactic medium (CGM) to be within $kT_{CGM}=0.153-0.178$ keV and $Z_{CGM}=0.052-0.072$ $Z_\odot$, depending on the contribution of solar wind charge exchange (SWCX). Slightly larger CGM abundances $Z_{CGM}=0.05-0.10$ $Z_\odot$ are possible, considering the uncertain extrapolation of the extragalactic Cosmic X-ray background (CXB) emission below $\sim1$ keV. To recover CGM abundances as large as $Z_{CGM}=0.3$ $Z_\odot$, it must be postulated the presence of an additional component, likely associated with the warm-hot intergalactic medium, providing $\sim15-20$% of the flux in the soft X-ray band. The emission in the soft band is dominated by the CGM, with contributions from the CXB and the local hot bubble. Moreover, the eROSITA data require the presence of an additional component associated with the elusive Galactic corona plus a possible contribution from unresolved M dwarf stars. This component has a temperature of $kT\sim0.4-0.7$ keV and it might be out of thermal equilibrium. It contributes $\sim9$% to the total emission in the 0.6--2 keV band, therefore it is a likely candidate to produce part of the unresolved CXB flux observed in X-ray ultra-deep fields. We also observe a significant contribution to the soft X-ray flux due to SWCX, during periods characterised by stronger solar wind activity, and causing the largest uncertainty on the determination of the CGM temperature.Comment: Accepted for publication in Astronomy and Astrophysic

Acute central nervous system toxicity during treatment of pediatric acute lymphoblastic leukemia : phenotypes, risk factors and genotypes

Publisher Copyright: © 2022 Ferrata Storti Foundation Published under a CC BY-NC license.Central nervous system (CNS) toxicity is common at diagnosis and during treatment of pediatric acute lymphoblastic leukemia (ALL). We studied CNS toxicity in 1, 464 children aged 1.0-17.9 years, diagnosed with ALL and treated according to the Nordic Society of Pediatric Hematology and Oncology ALL2008 protocol. Genome-wide association studies, and a candidate single-nucleotide polymorphism (SNP; n=19) study were performed in 1, 166 patients. Findings were validated in an independent Australian cohort of children with ALL (n=797) in whom two phenotypes were evaluated: diverse CNS toxicities (n=103) and methotrexate-related CNS toxicity (n=48). In total, 135/1, 464 (9.2%) patients experienced CNS toxicity for a cumulative incidence of 8.7% (95% confidence interval: 7.31-10.20) at 12 months from diagnosis. Patients aged ≥10 years had a higher risk of CNS toxicity than had younger patients (16.3% vs. 7.4%; P<0.001). The most common CNS toxicities were posterior reversible encephalopathy syndrome (n=52, 43 with seizures), sinus venous thrombosis (n=28, 9 with seizures), and isolated seizures (n=16). The most significant SNP identified by the genome-wide association studies did not reach genomic significance (lowest P-value: 1.11x10-6), but several were annotated in genes regulating neuronal functions. In candidate SNP analysis, ATXN1 rs68082256, related to epilepsy, was associated with seizures in patients <10 years (P=0.01). ATXN1 rs68082256 was validated in the Australian cohort with diverse CNS toxicities (P=0.04). The role of ATXN1 as well as the novel SNP in neurotoxicity in pediatric ALL should be further explored.Peer reviewe

Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry

Background: Nirmatrelvir/ritonavir treatment decreases the hospitalisation rate in immunocompetent patients with COVID-19, but data on efficacy in patients with haematological malignancy are scarce. Here, we describe the outcome of nirmatrelvir/ritonavir treatment in a large cohort of the latter patients. Methods: This is a retrospective cohort study from the multicentre EPICOVIDEHA registry (NCT04733729) on patients with haematological malignancy, who were diagnosed with COVID-19 between January and September 2022. Patients receiving nirmatrelvir/ritonavir were compared to those who did not. A logistic regression was run to determine factors associated with nirmatrelvir/ritonavir administration in our sample. Mortality between treatment groups was assessed with Kaplan-Meier survival plots after matching all the patients with a propensity score. Additionally, a Cox regression was modelled to detect factors associated with mortality in patients receiving nirmatrelvir/ritonavir. Findings: A total of 1859 patients were analysed, 117 (6%) were treated with nirmatrelvir/ritonavir, 1742 (94%) were treated otherwise. Of 117 patients receiving nirmatrelvir/ritonavir, 80% had received ≥1 anti-SARS-CoV-2 vaccine dose before COVID-19 onset, 13% of which received a 2nd vaccine booster. 5% were admitted to ICU. Nirmatrelvir/ritonavir treatment was associated with the presence of extrapulmonary symptoms at COVID-19 onset, for example anosmia, fever, rhinitis, or sinusitis (aOR 2.509, 95%CI 1.448-4.347) and 2nd vaccine booster (aOR 3.624, 95%CI 1.619-8.109). Chronic pulmonary disease (aOR 0.261, 95%CI 0.093-0.732) and obesity (aOR 0.105, 95%CI 0.014-0.776) were not associated with nirmatrelvir/ritonavir use. After propensity score matching, day-30 mortality rate in patients treated with nirmatrelvir/ritonavir was 2%, significantly lower than in patients with SARS-CoV-2 directed treatment other than nirmatrelvir/ritonavir (11%, p&nbsp;=&nbsp;0.036). No factor was observed explaining the mortality difference in patients after nirmatrelvir/ritonavir administration. Interpretation: Haematological malignancy patients were more likely to receive nirmatrelvir/ritonavir when reporting extrapulmonary symptoms or 2nd vaccine booster at COVID-19 onset, as opposed to chronic pulmonary disease and obesity. The mortality rate in patients treated with nirmatrelvir/ritonavir was lower than in patients with targeted drugs other than nirmatrelvir/ritonavir. Funding: EPICOVIDEHA has received funds from Optics COMMIT (COVID-19 Unmet Medical Needs and Associated Research Extension) COVID-19 RFP program by GILEAD Science, United States (Project 2020-8223)